**Kolmar BNH’s Immune Booster HemoHim Achieves FDA NAI Classification**
SEOUL, South Korea—Kolmar BNH (KRX: 200130), the manufacturer of the immune-boosting dietary supplement HemoHim, has achieved a significant milestone, as its Sejong facility in South Korea received a “No Action Indicated” (NAI) classification from the U.S. Food and Drug Administration (FDA). This classification reinforces the product’s credibility in the global marketplace.
HemoHim’s effectiveness has already been recognized by both the FDA and Australia’s Therapeutic Goods Administration (TGA). The supplement is designed to support and enhance the human immune system, a particularly appealing benefit in today’s health-conscious environment.
The NAI classification is a notable achievement, as it confirms compliance with FDA regulations upon inspection of the manufacturing facility. This status supports Kolmar BNH’s commitment to maintaining high standards in product quality and safety. The NAI classification is seen as a positive indicator for the product’s potential growth and acceptance in the U.S. market.
For biotech investors, this development signals promising expansion opportunities for Kolmar BNH in the global dietary supplement industry. With regulatory endorsements in key markets such as the U.S. and Australia, HemoHim’s marketability and consumer trust are poised to strengthen further.
For further details, visit the Business Wire release: [Learn More](http://www.businesswire.com/portal/site/home/news/industry